Backgrounds And Aims: Previous studies have investigated that sarcopenia is associated with nonalcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis, and fibrosis in NAFLD. The study aims to investigate the risk for NAFLD, especially NAFLD-related significant fibrosis among subjects with sarcopenia.
Methods: We searched electronic databases until 30, September 2017 and reviewed literature extensively. Effect estimates were pooled using random effect models regarding the risk for NAFLD and fixed effect models concerning the risk for significant fibrosis among sarcopenia patients. Sensitivity analysis was performed for the risk of NAFLD.
Results: We identified 6 studies. Our results showed that subjects with sarcopenia exhibited an increased risk for NAFLD compared to those without sarcopenia (OR 1.29, 95% CI 1.12-1.49) with heterogeneity among the individual studies (I2 = 61%). And the risk for NAFLD-related significant fibrosis appeared to be more pronounced in sarcopenia patients (OR 1.57, 95% CI 1.29-1.90) with an I2 of 0%. Sensitivity analysis revealed that neither the direction nor the magnitude of the estimated pooled results for NAFLD was obviously affected. Furthermore, the pooled ORs were both close to initial analysis when omitting the study by Hong et al. [Hepatology 2014; 59: 1772-1778] (OR 1.24, 95% CI 1.11-1.39, I2 = 47%) or by Hashimoto et al. [Endocr J 2016; 63: 877-884] (OR 1.33, 95% CI 1.11-1.59, I2 = 67%), which were considered sources of heterogeneity.
Conclusions: Our analysis demonstrated that sarcopenia served not only as a risk factor for the onset of NAFLD but also related to the progression of NAFLD-related significant fibrosis.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1159/000491015 | DOI Listing |
Medicine (Baltimore)
November 2024
Beatty Liver and Obesity Research Program, Inova Fairfax Medical Campus, Falls Church, VA.
Modifiable risk factors associated with cognitive functioning are important for identifying potential targets for intervention development. Although there are a few recognized modifiable risk factors (e.g.
View Article and Find Full Text PDFClin Exp Med
January 2025
Department of Hepatology and Gastroenterology, National Liver Institute, Menoufia University, Shebeen Elkoom, Menoufia, Egypt.
The diagnostic criteria for Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD) and Metabolic Associated Steatotic Liver Disease (MASLD) aim to refine the classification of fatty liver diseases previously grouped under Non-Alcoholic Fatty Liver Disease (NAFLD). This study evaluates the applicability of the MAFLD and MASLD frameworks in NAFLD patients, exploring their clinical utility in identifying high-risk patients. A total of 369 NAFLD patients were assessed using MAFLD and MASLD diagnostic criteria.
View Article and Find Full Text PDFEndocr Metab Immune Disord Drug Targets
January 2025
Department of Medicine, Hualien Armed Forces General Hospital, Hualien City, Taiwan.
Background: Plasma AST and ALT may reflect the nonalcoholic fatty liver disease (NAFLD) severity and have been associated with the risk of MetS in middle- or old-aged individuals.
Aims: This study aimed to examine the associations of plasma hepatic aspartate and alanine transaminases (AST and ALT) levels with incident metabolic syndrome (MetS) in young adults, which have not been verified before.
Objective: The goal of this study was to identify the association between plasma hepatic transaminases and the incidence of new-onset MetS among young adults.
Endocr Metab Immune Disord Drug Targets
January 2025
Department of Medicine, Hualien Armed Forces General Hospital, Hualien City, Taiwan.
Background: Hepatic inflammation, e.g., Nonalcoholic Fatty Liver Diseases (NAFLD) and the severe form of steatohepatitis (NASH), has been associated with a higher risk of MetS in the general population.
View Article and Find Full Text PDFJ Health Popul Nutr
January 2025
Department of Gastroenterology and Hepatology, The First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, No. 55 Zhenhai Road, Xiamen, 361003, China.
Purpose: Evidence concerning the effect of cardiovascular health (CVH) on the risk of metabolic dysfunctional-associated steatotic liver disease (MASLD) is scarce. This study aimed to investigate the association between CVH and MASLD.
Methods: 5680 adults aged ≥ 20 years from the National Health and Nutrition Examination Survey 2017-March 2020 were included.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!